Haloperoxidase enzymes, myeloperoxidase
(MPO) and eosinophil peroxidase (EPO), work to kill a broad range of pathogens
through a unique mechanism of action unlikely to induce resistance.
Exoxemis products are built on the fundamental discovery that myeloperoxidase
(MPO) and eosinophil peroxidase (EPO) bind preferentially and kill pathogenic
bacteria, viruses, and fungi with minimal damage to host tissue. Induction
studies in clinically important bacterial isolates found that resistance
to MPO did not develop.
Fast-working formulations, broad-spectrum effectiveness
Exoxemis has created a broad proprietary base of predictive models, know-how,
and intellectual property that form the foundation for commercialization
efforts.
Extensive in vitro and in vivo testing demonstrate that
our formulations are safe and rapidly cidal against a broad range of microbiological
targets, including gram-negative and gram-positive bacteria, spores, fungi,
and viruses. The unique characteristics of the MPO system are:
- True broad-spectrum activity
- Effective against drug-resistant organisms
- Active at very low concentrations
- Demonstrated efficacy
- Safe in multiple species
- Unique mechanism of action unlikely to induce antimicrobial resistance
|
